<?xml version="1.0" encoding="UTF-8"?>
<p>The investigation of the anti-SARS-CoV-2 activity of CQ and HCQ is also encouraged by several factors. First, both CQ and HCQ have been used for the treatment and prophylaxis of malaria and rheumatic diseases for more than 50 years. Second, both drugs are very cheap, e.g., when compared with immunotherapy. Finally, CQ inhibits the synthesis of a myriad of pro-inflammatory cytokines such as TNF-Î±, IL-1, and IL-6 [
 <xref rid="B106-pharmaceuticals-13-00096" ref-type="bibr">106</xref>], which may have deleterious effects on COVID-19 prognosis.
</p>
